A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan

Supportive Care in Cancer

Volumn 23, Issue 3, 2015, Pages 661-670

  Kee, Bryan K ^a   Morris, Jeffrey S ^a   Slack, Rebecca S ^a   Crocenzi, Todd ^b   Wong, Lucas ^c   Esparaz, Ben ^d   Overman, Michael ^a   Glover, Katrina ^e   Jones, Desiree ^a   Wen, Sijin ^f   Fisch, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Columbia River Oncology Program ^*  (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d Central Illinois CCOP   (United States)

^e Tyler Hematology Oncology   (United States)

^f WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Calcium aluminosilicate clay (CASAD); Colorectal cancer; Diarrhea; Irinotecan

Indexed keywords

ALUMINOSILICATE CALCIUM; BEVACIZUMAB; CETUXIMAB; FIRTECAN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB; PLACEBO; ALUMINUM SILICATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ADSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; M.D. ANDERSON SYMPTOM INVENTORY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; STATISTICAL ANALYSIS; SYMPTOM; TREATMENT DURATION; ADULT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALUMINUM SILICATES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922221571     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2402-1     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166
2. Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27(12):1948–1955. doi:10.1200/JCO.2008.20.2879
3. Kemeny NE (2013) Treatment of metastatic colon cancer: “the times they are A-changing”. J Clin Oncol 31(16):1913–1916. doi:10.1200/JCO.2013.49.4500
4. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352(5):476–487. doi:10.1056/NEJMra040958
5. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011–2019. doi:10.1200/JCO.2010.33.5091
6. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, Bondarenko I, Jonker DJ, Sun Y, De la Cruz JA, Williams JA, Korytowsky B, Christensen JG, Lin X, Tursi JM, Lechuga MJ, Van Cutsem E (2013) Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 31(10):1341–1347. doi:10.1200/JCO.2012.45.1930
7. Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH, Bodoky G, Habboubi N, Garay C, Olivatto LO (2008) Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26(28):4544–4550. doi:10.1200/JCO.2008.17.1249
8. Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC (2009) Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 27(17):2848–2854. doi:10.1200/JCO.2008.20.4552
9. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S (2008) Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 26(33):5335–5343. doi:10.1200/JCO.2008.16.3758
10. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, Wadler S (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918–2926. doi:10.1200/JCO.2004.04.132
11. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21(5):807–814
12. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25(30):4779–4786. doi:10.1200/JCO.2007.11.3357
13. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905–914. doi:10.1056/NEJM200009283431302
14. Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2(1):51–63. doi:10.1177/1758834009355164
15. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16(8):2745–2751
16. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J, Keefe DM (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 232(1):96–106
17. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84(6):697–702
18. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047
19. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 28(4):423–433
20. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56(16):3752–3757
21. Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87(24):1876–1883
22. Phillips TD (1999) Dietary clay in the chemoprevention of aflatoxin-induced disease. Toxicol Sci 52(2 Suppl):118–126
23. Wang JS, Luo H, Billam M, Wang Z, Guan H, Tang L, Goldston T, Afriyie-Gyawu E, Lovett C, Griswold J, Brattin B, Taylor RJ, Huebner HJ, Phillips TD (2005) Short-term safety evaluation of processed calcium montmorillonite clay (NovaSil) in humans. Food Addit Contam 22(3):270–279. doi:10.1080/02652030500111129
24. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M (1995) Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6(2):133–140
25. Asao T, Buechi G, Chang SB, Abdel-Kader MM, Wick EL, Wogan GN (1965) The structures of aflatoxins B and G. J Am Chem Soc 87:882–886
26. Han KA, Carpenter RH (2008) Calcium aluminosilicate (CAS) in the treatment of intractable diarrhea in dogs with cancer. Intern J Appl Res Vet Med 6:181–184
27. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634–1646
28. Kahouli I, Tomaro-Duchesneau C, Prakash S (2013) Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J Med Microbiol 62(Pt 8):1107–1123. doi:10.1099/jmm.0.048975-0
29. Fuccio L, Guido A, Eusebi LH, Laterza L, Grilli D, Cennamo V, Ceroni L, Barbieri E, Bazzoli F (2009) Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. J Clin Gastroenterol 43(6):506–513. doi:10.1097/MCG.0b013e3181a1f59c
30. Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM, (MASCC/ISOO) MSGotMAoSCiCISoOO (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21(1):313–326. doi:10.1007/s00520-012-1644-z
31. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K (2001) Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92(2):269–275
32. Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA (2010) Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst 102(8):547–556. doi:10.1093/jnci/djq063
33. Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P, Wendling JL, Burki F, Mignard D, Marty M (2000) Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 23(2):143–148
34. Flieger D, Klassert C, Hainke S, Keller R, Kleinschmidt R, Fischbach W (2007) Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 72(1–2):10–16. doi:10.1159/000111083
35. Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ (2004) Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 22(21):4410–4417. doi:10.1200/JCO.2004.11.125